PRAX — Praxis Precision Medicines Share News
0.000.00%
Last trade - 00:00Brief: Praxis Precision Medicines To Host Conference Call To Announce Topline Results From The Radiant Trial And Provide Second Quarter 2025 Financial Results
U.S. RESEARCH ROUNDUP-Hershey, Metlife, Voya Financial
Brief: Praxis Precision Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Praxis Precision Q1 EPS USD -3.29 Vs. IBES Estimate USD -3.2
Brief: Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Praxis Precision Medicines Inc reports results for the quarter ended December 31 - Earnings Summary
U.S. RESEARCH ROUNDUP- Autodesk, Fedex, Morgan Stanley Direct Lending Fund
U.S. STOCKS ON THE MOVE-BridgeBio Pharma, NetApp, Talen Energy
U.S. STOCKS ON THE MOVE-Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines
Praxis slumps as anti-tremor drug study unlikely to meet the main goal
Praxis' tremor drug trial unlikely to meet main goal (updated)
Independent committee says Praxis' tremor drug trial unlikely to meet main goal
Brief: Praxis Precision Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Apple, Murphy USA, UnitedHealth
Brief: Praxis Precision Medicines Inc Files For Mixed Shelf
Brief: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted For Relutrigine In Dravet Syndrome
Brief: Praxis Precision Q3 EPS USD -2.75 Vs. IBES Estimate USD -1.99
Praxis Precision Medicines Inc expected to post a loss of $1.99 a share - Earnings Preview
Praxis Precision Medicines Inc reports results for the quarter ended in June - Earnings Summary